ReviewBiotechnology journal2026
Harnessing Nature's Algorithm: From Test Tubes to Autonomous In Vivo Evolution.
Review in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Directed evolution (DE) enables the engineering of biomolecules without prior structural knowledge. However, traditional step-wise DE is constrained by limited screening throughput. To more efficiently navigate epistatic fitness landscapes, the field is increasingly adopting autonomous, continuous in vivo evolution systems. This review critically examines the molecular architectures and engineering principles driving this transition. We evaluate strategies for continuous genetic diversification-ranging from orthogonal replication systems (e.g., OrthoRep, T7-ORACLE) to CRISPR-guided mutagenesis (e.g., EvolvR)-with a focus on the fundamental trade-off between mutational load and host viability. Furthermore, we analyze the biophysical constraints of screening and the kinetic demands of coupling real-time selection with ultra-fast mutagenesis, as exemplified by phage-assisted continuous evolution (PACE). Crucially, we explore the functional integration of machine learning (ML), highlighting how active learning models and zero-shot predictions via protein language models (PLMs) can resolve epistatic complexities and mitigate the latency of next-generation sequencing. Finally, we discuss the multidimensional hardware and algorithmic bottlenecks currently impeding the realization of fully closed-loop biofoundries, and assess the strategic implications of these technologies for accelerating the engineering of complex therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.